Company
Highlight Therapeutics
We develop dermato-oncology treatments with the goal of healing and curing disease and conditions beyond skin-deep.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Headquarters
- Madrid, Spain
- highlighttherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Funding snapshot
- Latest round
- Undisclosed2025-09-04
Funding rounds
- Round, 2025
- 2025-09-04
Products
- Other
- BO-112
Loading relationship preview